pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery
company, today announced that Dr. Paul Ashton, President and Chief
Executive Officer, will make a presentation on ocular drug delivery
systems at the fifth annual IBC International Conference on Ocular
Angiogenesis and Retinal Degeneration, to be held in Las Vegas, March 30
and 31. The Conference provides state-of-the-art research information on
therapeutic development for ocular disease including research targeting
unmet needs and therapeutic advances that improve available treatment
options.
About pSivida Corp.
pSivida is a world leader in the development of miniaturized,
injectable, drug delivery systems for the eye. pSivida has two products
approved by the Food and Drug Administration (FDA): Retisert®
to treat uveitis and Vitrasert® for treating AIDS-related
cytomegalovirus (CMV) retinitis. pSivida has licensed both of these
products and the technologies underlying them to Bausch & Lomb
Incorporated. pSivida has one product in fully recruited Phase III
clinical trials: Iluvien™, which delivers fluocinolone acetonide (FA)
for the treatment of diabetic macular edema (DME), formerly known as
Medidur FA for DME. pSivida has licensed certain drug delivery
technology to Alimera Sciences, Inc. for the development of Iluvien and
certain other ophthalmic products. pSivida has a worldwide collaborative
research and license agreement with Pfizer Inc. under which Pfizer may
develop additional ophthalmic products.
pSivida owns the rights to develop and commercialize a modified form of
silicon known as BioSilicon™, which has potential therapeutic
applications. The most advanced BioSilicon product candidate,
BrachySil™, delivers a therapeutic P32, a radioactive form of phosphorus
used to treat cancer, directly to solid tumors. pSivida completed an
initial safety and efficacy clinical trial of BrachySil for the
treatment of pancreatic cancer and has commenced a dose-ranging clinical
trial.
pSivida’s intellectual property portfolio consists of 45 patent
families, over 100 granted patents, including patents accepted for
issuance, and over 200 patent applications. pSivida conducts its
operations from Boston in the United States and Malvern in the United
Kingdom.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are forward-looking
and involve a number of risks and uncertainties.
